(
out of
70
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
Clinic 2C, Dermatology/Melanoma
1950 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
4.8
/5
( out of
70 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Associate Professor |
|---|---|
| Academic Divisions |
Oncology
|
| Board Certification |
American Board of Internal Medicine (Sub: Medical Oncology)
|
Education history
| Professional Medical | Medicine - China Medical University | M.D. |
|---|---|---|
| Doctoral Training | Pathobiology - Keck School of Medicine, University of Southern California | Ph.D. |
| Postdoctoral Fellowship | Pathology - Children¿s Hospital Los Angeles | Postdoctoral Fellow |
| Internship/Residency | Internal Medicine - University of Southern California | Intern/Resident |
| Fellowship | Hematology/Oncology - David Geffen School of Medicine, University of California Los Angeles | Clinical Fellow |
Selected Publications
Journal Article
- Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis M (2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjugate chemistry, 16(5), 1071-80.
- Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz H (2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of oncology, 22(1), 104-9.
- Hu-Lieskovan S, Zhang J, Schofield DE, Shimada H, Wu L, Triche T (2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer research, 65(11), 4633-44.
- Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche T (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer research, 65(19), 8984-8992.
- Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo R (2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 165(1), 35-44.
- Zaretsky JM, Garcia Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Rodriguez GA, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez P, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher T, Lo RS, Ribas (2016). Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England journal of medicine, 375(9), 819-29.
- Eroglu Z,* Zaretsky J,* Hu-Lieskovan S,*¿ Kim DW, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Homet Moreno B, Cherry G, Berent-Maoz B, Comin-Anduix B, Wang X, Tumeh PC, Shintaku IP, Hugo W, Lo RS, Sosman JA, Joseph R, Postow M, Hwu W-J, Messina J, Long G, Ribas A ¿. (*Equal contribution as first authors, ¿ Corresponding authors (2018). High response to PD-1 blockadein desmoplastic melanoma. Nature, 553(7688), 347-350.
- Zhang J, Hu S, Schofield D, Sorensen P, Triche T (2004). Selective usage of D type cyclins by Ewing's tumors and rhabdomyosarcomas. Oncogene, 64(17), 6026-34.
- Zwerner P, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May W (2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene, 27(23), 3282-91.
- Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore (2018). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proceedings of the National Academy of Sciences of the United States of America,
- Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz H (2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. . Clinical cancer research, 17(15), 5161-9.
- Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow L (2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Clinical cancer research,
- Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna A (2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical cancer research,
- Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran A, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (2019). A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clinical cancer research, 25(7), 2096-2108.
- Hu-Lieskovan S, Lisberg A, Zaretsky J, Wells D, Han M, Shintaku I, Wolf B, Abarca P, Slamon D, Goldman JW, Dubinett S, Ribas A, Garon EB (2019). Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clinical cancer research,
- Diab A, Hamid O, Thompson J, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner S, Ganguly B, Fleener C, Wang X, Jo T, Liao K, Salek-Ardakani S, Taylor C, Chou J, El-Khoueiry (2021). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers. Clinical cancer research,
- Heidel JD, Hu S, Liu XF, Triche TJ, Davis M (2004). Lack of interferon response in animals to naked siRNAs. Nature biotechnology, 22(12), 1579-82.
- Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas (2015). Inhibition of CSF-1R Improves Antitumor Efficacy of BRAF Inhibition. BMC cancer, 15(1), 356.
- Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang (2019). Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell stem cell, 25(4), 542-557.e9.
- Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Koya KC, Graeber T, Comin-Anduix B, Ribas (2015). Improved Antitumor Activity of Immunotherapy with BRAF and MEK inhibitors in BRAFV600E mutant melanoma. Science translational medicine, 7(279), 279.
- Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych DH, Ribas (2020). Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature communications, 11(1), 660.
- Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas (2016). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer discovery,
- Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters (2018). Genetic mechanisms of immune evasion in colorectal cancer. Cancer discovery,
- Homet Moreno B, Mok S, Robert L, Comin-Anduix B, Hu-Lieskovan S, Ribas (2015). Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma. Oncoimmunology, 5(7), e1052212.
- Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell reports, 19(6), 1189-1201.
- Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom J (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer medicine,
- Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter S (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA dermatology, 156(9), 1004-1011.
- Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami (2021). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. Journal for immunotherapy of cancer,
- Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker H (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. Journal for immunotherapy of cancer, 8(2),
- Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S,* Ribas A* (*Corresponding Authors (2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer immunology research, 4(10), 845-857.
- Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan (2019). Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA oncology,
- Abril-Rodriguez G, Torrejon T, Zaretsky J, Nowicki T, Tsoi J, Baselga Carretero I, Medina E, Quist M, Senapedis W, Baloglu E, Cheung-Lau G, Puig-Saus C, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Grasso C, Ribas (2019). PAK4 inhibition reverses T cell exclusion in cancer and improves PD-1 blockade immunotherapy. Nature cancer, 1, 46-58.
- Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs C (2019). Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. Journal for immunotherapy of cancer, 7(1), 119.
- Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson M (2021). Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Targeted oncology, 16(6), 773-787.
- Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen S (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer reports (Hoboken, N.J.), 4(6), e1419.
- Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry A (2022). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clinical cancer research, 28(1), 71-83.
- Poran A, Scherer J, Bushway ME, Besada R, Balogh KN, Wanamaker A, Williams RG, Prabhakara J, Ott PA, Hu-Lieskovan S, Khondker ZS, Gaynor RB, Rooney MS, Srinivasan (2020). Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.
- Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347-362.e24.
- Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas (2020). PAK4 inhibition improves PD-1 blockade immunotherapy. Nature cancer, 1(1), 46-58.
- Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas (2020). Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nature cancer, 1(2), 264.
- Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer discovery, 10(8), 1140-1157.
- Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry A (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for immunotherapy of cancer, 10(10),
- Yap T, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow (2022). A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clinical cancer research,
- Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas (2023). Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine, 388(9), 813-823.
- Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in immunology,
- VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. . Nature Medicine,
- Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH (2023). The New NCI Precision Medicine Trials. Clinical cancer research,
- Magdalena Kovacsovics-Bankowski, Johanna M. Sweere, Connor P. Healy, Natalia Sigal, Li-Chun Cheng, William D. Chronister, Shane A. Evans, John A. Marsiglio, Berit Gibson, Yoko S. Derose, Annaleah Larson, Carlos O. Medina, Ramji Srinivasan, Matthew H. Spitzer, Ngan Nguyen, John R. Hyngstrom, Hu-Lieskovan (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in checkpoint inhibitor-treated melanoma. Journal for immunotherapy of cancer,
- Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current oncology (Toronto, Ont.),
- Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC (2024). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. The oncologist, 29(5), 415-421.
- Marsiglio J, McPherson J, Wahl M, Hu-Lieskovan (2024). Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature. Melanoma research,
- Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill AE (2025). Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer epidemiology, biomarkers & prevention,
- Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kope'ek J, Yang J (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. Journal of controlled release,
- Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, Mcarthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM (2024). Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. . European journal of cancer (Oxford, England,
- Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer EA (2024). Comparing the rate of immunotherapy treatment change due to toxicity by sex. . Cancer reports (Hoboken, N.J.),
- Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill A (2025). Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer epidemiology, biomarkers & prevention, 34(6), 860-867.
- Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kope'ek J, Yang (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. Journal of controlled release, 382, 113682.
- Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current oncology (Toronto, Ont.), 32(3),
- Li J, Arnold J, Sima M, Al Faruque H, Galang J, Hu-Lieskovan S, Kope'ek J, Yang (2024). Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. Journal of controlled release, 376, 1014-1024.
- Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, Mcarthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies A (2024). Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. European journal of cancer (Oxford, England, 212, 115055.
- Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan A (2024). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. The oncologist, 29(5), 415-421.
- Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer E (2024). Comparing the rate of immunotherapy treatment change due to toxicity by sex. Cancer reports (Hoboken, N.J.), 7(2), e1932.
- Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. Journal for immunotherapy of cancer, 12(1),
- Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow J (2023). The New NCI Precision Medicine Trials. Clinical cancer research, 29(23), 4728-4732.
- Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in immunology, 14, 1229823.
- Piper M, Kluger H, Ruppin E, Hu-Lieskovan (2023). Immune Resistance Mechanisms and the Road to Personalized Immunotherapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43, e390290.
- VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature medicine, 29(9), 2278-2285.
- Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan (2023). Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis. Research square,
- Zhang W, Zhou Q, Nguyen JV, Egal E, Yang Q, Freeman MR, Hu-Lieskovan S, Suneja G, Coghill A, Knudsen B (2025). Comparison of QuPath and HALO platforms for analysis of the tumor microenvironment in prostate cancer. bioRxiv,
- Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill A (2025). Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer epidemiology, biomarkers & prevention,
- Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kope'ek J, Yang (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. Journal of controlled release,
- Li J, Al Faruque H, Cortes-Sanchez E, VanBrocklin M, Hu-Lieskovan S, Cina M, Young A, Kope'ek J, Yang (2025). Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma. Journal of controlled release, 387, 114193.
- Zhang W, Zhou Q, Nguyen JV, Egal E, Yang Q, Freeman MR, Hu-Lieskovan S, Suneja G, Coghill A, Knudsen B (2025). Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer. Laboratory investigation; a journal of technical methods and pathology, 105(12), 104246.
- Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas (2025). Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nature medicine,
- Winn M, Pauleck S, Richardson S, Viskochil R, Karra P, Colman H, Doherty JA, Xu Y, Hu-Lieskovan S, Litchman M, Playdon MC, Hardikar (2025). New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study. Diabetes, obesity & metabolism,
Review
- Robert L, Ribas A, Hu-Lieskovan (2016). Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2?. Seminars in immunology, 28(1), 73-80.
- Sharma P, Hu-Lieskovan S, Wargo J, Ribas (2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168(4), 707-723.
- Moser J, Hu-Lieskovan (2020). Mechanisms of Resistance to PD-1 Checkpoint Blockade. Drugs, 80(5), 459-465.
- Ribas A, Hu-Lieskovan (2016). What does PD-L1 positive or negative tumors mean? Perspective for Clinical Correlates of Immunotherapy. The Journal of experimental medicine, 213(13), 2835-2840.
- Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas (2014). Combining targeted therapy with immunotherapy in BRAF mutant melanoma: promise and challenges. Journal of clinical oncology, 32(21), 2248-2254.
- Hu-Lieskovan S, Ribas (2017). New combination strategies using PD-1/ L1 checkpoint inhibitors as a backbone. Cancer journal (Sudbury, Mass.), 23(1), 10-22.
- Nowicki T, Hu-Lieskovan S, Ribas (2018). Mechanisms of Resistance to PD-1 and PD-L1 blockade. Cancer journal (Sudbury, Mass.), 24(1), 47-53.
- Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs I, Chou J, Salek-Ardakani S, Kraynov (2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Journal for immunotherapy of cancer, 7, Article: 105.
- Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson M (2021). Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future oncology (London, England), 17(11), 1401-1439.
- Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami (2021). The dark side of immunotherapy. Annals of translational medicine, 9(12), 1041.
- Yuan J, Khilnani A, Brody J, Andtbacka RHI, Hu-Lieskovan S, Luke JJ, Diab A, Marabelle A, Snyder A, Cao ZA, Hodi F (2021). Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. European journal of cancer (Oxford, England, 157, 493-510.
- Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan (2022). The role of biomarkers in personalized immunotherapy. Biomarker research, 10(1), 32.
Book Chapter
- McKean W, Moser J, Rimm D, Hu-Lieskovan (2020). Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, e275-e291.
- Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan (2019). Mechanisms of Resistance to Immune Checkpoint Blockade: Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, (39), 147-164.
- Sharma S, Hu-Lieskovan S, Dubinett SM, Moon Lee (2015). Addressing inflammation with immunotherapy.
- Hu-Lieskovan S, Chmielowski B, Ribas (2017). Cancer Immunotherapy.
- Piper M, Kluger H, Ruppin E, Hu-Lieskovan S (2023). Immune Resistance Mechanisms and the Road to Personalized Immunotherapy.
Commentary
- McKean W, Hu-Lieskovan (2021). Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection. . ASCO Daily News,
Editorial
- Hu-Lieskovan S, Homet Moreno B, Ribas (2015). Excluding T cells: Is β-catenin the full story?. 27(6), 749-750.
- Pal S, Hu-Lieskovan S, Agarwal (2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?. 20(11), 1473-1474.
Letter
- Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng (2022). CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal transduction and targeted therapy, 7(1), 224.
Abstract
- Hu-Lieskovan S, Kari Kendra, Kai He, Bently Doonan, Eric Schaefer, Edward Arrowsmith, Ki Chung, Eric Whitman, Ulka Vaishampayan, Svetlana Shpyro, Karrie Wang, Juanjuan Su, Chris Leung, Kazu Kai, Yang Liu, Pan Zheng, Tianhong L (2025). Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors. ASCO 2025.
Other
- Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas (2025). Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nature medicine,
Video/Film/CD/Web/Podcast
- Hu-Lieskovan S, Ribas (2013). ASCO 2013 Highlights: Melanoma (review).
Research Lab
Lab link
Siwen Hu-Lieskovan, MD is a brilliant oncologist. She helped my husband and me understand my future treatments options. We sincerely appreciated her explanations, personal perspective, and true concern for my diagnosis. We truly love Dr. Hu-Lieskovan!!!
The Doctor spent a significant amount of time explaining my condition, my choices, how the treatment works and potential risks.
I feel very confident in Dr. Hu, her knowledge, understanding of my health needs and her care, as well as that of my whole team at Huntsman.
For this visit most of these questions were irrelevant. We're waiting for the scans that will be done in January to see the trajectory of the disease and the doctor did not discuss what the treatment option choices might be based on what is seen on the upcoming scans. I think I would have preferred for the doctor to speculate a bit about the future but I was OK with waiting.
again very through
The doctor was awesome and explained things a lot better then they have been explained to me before. She showed care for me and helped me understand what she was saying and why she was saying the direction she wanted to go.
She was very caring, very prepared, very intelligent, very personable. She had options for future treatments. I felt very comfortable with her.
Thank you for your help understanding the TEMPUS test and respecting my life's choices!
Amazing Doctor Cares for your well being.
She showed me all the options and then made the decision going forward. I trust her completely.
We appreciate your support, patients and dedication to this extremely important field of work. Thank you!
Smart and explains well
I have an extremely capable team, always looking out for me
I can't say enough positive things about Dr Hu, she is very knowledgeable, caring, patient, takes time to explain, demonstrates compassion and empathy.
While I seem to be very healthy and have no known metastasis at this 1-year point, I appreciate the caution shown by the additional diagnostics now planned to be more sure of my condition: a PET scan to better see some nodules in lungs and an endoscopy to check if GERD-like symptoms may be due to something worse going on in the upper GI.
Dr. Hu, is a very thoughtful, intelligent, caring Doctor. I would recommend to everyone.
Dr. Hu took the time needed to talk to me and answer my questions. She seemed relaxed and not rushed as she spoke with me, one-on-one. I really appreciated this personal care.
Waited more than 30 min for her come in
She knew every detail of my previous treatments & presented a plan for future treatment with care & making sure I understood all the details of the plan & how the cancer treatment worked. She made me feel like she really cares about each individual patient.
Very smart doctor and very kind
She has been wonderful. I am so greatful to have her for my Dr. Thank you soooo much!
Allowing me to be a part of decisions about my care "Excellent!"
I appreciated that she took so much time discussing the scan results with us and explaining what they might mean. It was unexpected and disappointing "bad news" and I think she handled it very well - she was helping us to be prepared to choose among the treatment options if biopsy confirms a recurrence of malignancy.
Dr. was very thorough and took her time to listen and answer all questions. You could tell she cares for the well being of her patients
Dr. Hu was very patient, knowledgeable and respectful.
Dr Hu Lieskovan is very knowledgeable, kind, compassionate and empathetic. She really cares about the well-being of her patients. Not living in Utah, I looked forward to my appointments with her. My confidence in her, her demeanor gave me a great deal of confidence in the treatment she provided that clearly made me a lot more comfortable mentally.
Outstanding skill set with tender concern
Dr Hu is the very best.
Your reputation proceeds you!!!
Still no answers about my pain. I didn't know why I had to drive all that way to see the St for 10 minutes
Dr. Who, as she is fondly known as within the medical staff and patients was highly professional, friendly. She expedited my needed MRI and CT scan, and my first infusion. All were completed in one day, which was very beneficial to us, who live about 270 miles from your facilities.
I was very glad we made the effort to drive to SLC for the appointment.
The doctor was absolutely fantastic! I feel so good bout her directing my immunotherapy treatments!
Dr. Hu-Lieskovan is awesome! She took the necessary time needed to thoroughly explain my diagnosis and answered all of our questions regarding treatment. We didn't feel like we were being rushed in and out of the office.
Extremely knowledgeable about the subject matter that needed to be discussed. Have all the confidence in the world in the doctors here
Dr. Siwen Hu-Lieskovan, is highly intelligent and caring. She listened carefully and did research to help provide solutions to my concerns. She also provided referrals to follow up care with other providers. She shows that her number 1 objective is the best care possible for her patients
Best Doctor I have ever had in my life. She cares about each and every patient like we are family!!
Dr. Hu-Lieskovan is an expert on melanoma and treatments available. I have had to go thru several different treatments before we settled on one that was working for me. She explains things clearly and is compassionate in her service.
Professional, provided excellent background and treatment information on my diagnosis.
I feel so fortunate to have Dr. Hu-Lieskovan as my primary physician.
Dr Hu is so amazing. She always explains my treatment plan & answers all my questions. Dr. Hu continually gives me the confidence I have the very best care from Melanoma Team at the Huntsman.
She was very knowledgeable but sometimes difficult to understand with her mask on
She was very knowledgeable and professional
Her job she said was to educate us about the pros and cons and the side effects of the immuno therapy injections. She spent a very long time with us as did Dan the pharmacist answering many questions.
I feel that Dr. Hu-Liescovan is one of the best cancer Doctors out there. I feel very lucky to be here.
Dr Hu is so amazing. She always explains my treatment plan & answers all my questions. Dr. Hu continually gives me the confidence I have the very best care from Melanoma Team at the Huntsman.
Dr Hu is brillant and her knowledge of my issues was very impressive and comforting.
Professional, listened to me, talked me through my concerns, very highly qualified.
Excellent Doctor who cares for her patients
Dr. Hu-Lieskovan is a excellent dr. This was my 1st. visit with. She explained everything that I might be going through.
I had quite a history coming in to Huntsman she was aware of my path to the appointment.
She is an awesome doctor. Very thorough, checked my understanding, very knowledgeable. Glad I have her on my care team.
If you are in life and death situation, the person you want on your side is Dr Hu- Lieskovan
Dr. Hu was fantastic.
Dr Hu has been fantastic, shows concern, is knowledgeable and empathetic - she is the best
First time seeing Dr. Hu-Lieskovan & she exceeded my expectations! She was so engaged with my care & really listened to & answered all my questions. My confidence in my medical needs being met soared. I am honored & happy to be under her care. Dr. Hu-Lieskovan's expertise allows me to have quality of life as I travel thru this Melanoma journey. 5++++++ rating!
I've never had a physician give me such focused attention, for so long a time. Dr. Hu-Lieskovan thoroughly explained my diagnosis and possible treatments and left me with absolutely no doubt that I am receiving the best possible cancer care. I am so very grateful.
Thanks again! Great care
Incredibly compassionate and intelligent.
Exelent care. Very knowledgable about my case. Caring, getting my input in the matters of concern.
Very good took her time explaining everything extremely polite professional and up front and honest with my diagnosis
I have been impressed by Dr. Hu-Lieskovan's preparation for each visit along with the follow-through of her and the other team members each time that treatment plan changes have been necessary. I feel very fortunate to have had her expertise brought to bear upon my case during the nearly four years of treatment and surveillance since my diagnosis with acral melanoma at stage IIIC. I have been pleased with her assessments of treatment effectiveness and toxicity effects during this time, and the adjustments she has recommended. While so far the disease still progresses, I feel fortunate to have a very normal daily life due in part to the careful way that she practices medical oncology.
Dr. Hu exudes competence and kindness.
there's so much information to try and understand we are thankful to have the time we have and ask the questions that we do.
Very good and helpful
Dr. Hu was so helpful in explaining my condition, treatment options and possible side effects, etc. It was a lot of information, and she had answers for each question / concern and I have total confidence in her ability to provide the best care and treatment options available. I am so grateful to have her for my care provider and appreciate her very much.
I feel very well taken care of with Dr Hu in charge of my health. I am very confident that what is best for me is always her highest priority .
Recommend highly, gave me great comfort during my treatment.
Dr. Hu-Lieskovan was very impressive. Her depth of experience and knowledge about managing melanoma made me feel optimistic about my treatment plan. She was compassionate and spent a lot of time with me and my wife. I give her high marks across the board.
Dr. Hu thoroughly explained everything thoroughly - scan and lab results and my overall general health. She is very easy to talk to, listening and responding to all of my questions and concerns.
Great
Did not listen or respect my choices. I listened to more information about dermatologist melanoma than my uveal melanoma. I had to wade through too much information. I just wanted to say "FOCUS" on the type of cancer that I have and please don't compare it over and over in front of me to other cancers. That is something you can spend time doing with the medical team outside my presence. Please take time to learn and come prepared to present information to me about the type of cancer that I have.Please let me make choices for my life in this incurable uveal melanoma! A tumor not growing is not irrelevant information.
Personal able and professional.
She was very knowedgable and forthcoming. Expained what she thought was the proper course of treatment and why. Good experience!!
Still no answers about my pain. I didn't know why I had to drive all that way to see the St for 10 minutes
She explained things god and have a high concern on making you well.
She took a lot of time explaining my situation. Had all my questions answered.
Very sincere on my care. Just a great person!
Allowing me to be a part of decisions about my care "Excellent!"
See previous comments on first page. I am very confidant while placing my care plan in her hands.
Dr. Lieskovan makes your health a priority and she will keep you safe. She will give her patients her very best each and every time. She is the Cadillac of doctors and cancers worst enemy.
Always excellent input on reviewing my scans. Very satisfied with her care throughout my cancer treatment.
Excellent presentation a nd concern
She is very professional in her explanations.
Thank you for everything you do!
Felt comfortable and that she cared
I've been trusting Dr Hu for many years
Very professional